[Articles] Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial

Author profile image Aggregator
0 comments
Oral edaravone was well tolerated but did not significantly slow functional decline versus placebo over 48 weeks. These results do not support its use at the tested dose for modifying disease progression in the general amyotrophic lateral sclerosis population and highlight the need for the development of more effective therapeutic strategies.

Source: The Lancet Neurology - Current Issue Published 30 Nov 2026 Imported 19 Nov 2026 Relevancy: Not reviewed

Read the article